Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Organisation › Details

Yumab GmbH

YUMAB GmbH is a German biotechnology company founded in 2012 by scientists of University Braunschweig based on their long and excellent track record in antibody technologies. YUMAB provides technologies and contract research for the discovery and development of fully human antibodies for all therapeutic fields. In little more than six years, the company has become a global player in human monoclonal antibody development and drives the general trend in the immunotherapy space toward the use of fully human antibodies for immunotherapies. In 2018, YUMAB relocated its headquarter and labs to the Science Campus Braunschweig-South, where the company has new opportunities to thrive in an outstanding scientific infrastructure, collocated with the Helmholtz Centre for Infection Research (HZI). *


Period Start 2012-01-01 splitoff
  Predecessor Technical University Braunschweig (TU Braunschweig)
Products Industry MAb, human, fully
  Industry 2 phage display technology
Person Person Schirrmann, Thomas (Yumab GmbH 201907 Managing Director)
Region Region Braunschweig
  Country Germany
  Street 7 Inhoffenstr.
  City 38124 Braunschweig
  Tel +49-531-481170-0
    Address record changed: 2019-08-07
Basic data Employees n. a.
    * Document for �About Section�: Yumab GmbH. (7/22/19). "Press Release: Yumab Announces New Research and Collaboration Agreement with Merck". Braunschweig.
Record changed: 2019-08-07


Picture [LSA] – The Business Web Portal 650x89px

More documents for Yumab GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top